For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Group newsletter: CCTG Connection

Archived Bulletins

February 19, 2020

Published: February 19, 2020
Category: News
Supporting the Canadian arm of the ME15 international trial

CCTG has been awarded $1,303,560 from the Fall 2019 CIHR Project Grant competition, a program that helps advance health-related research. The funds will support the Canadian contribution to the ME15 international trial, investigating use of smaller surgical margins to reduce the extent of surgery in Stage 2 melanoma patient - Larger margins result in disfigurement, wound discomfort, and time away from work and, if positive, will change practice in Canada and around the world.

Read More

February 05, 2020

Published: February 05, 2020
Category: Group updates
 Seeking nominations for the 2020 CCTG Recognition Awards

The Canadian Cancer Trials Group is seeking nominations for the 2020 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Canadian Cancer Trials Group.

Read More

Published: February 05, 2020
Category: Group updates
The 2020 CCTG Annual Spring Meeting of Participants will be here before you know it! Make sure that you save the date: May 1 - 3, Chelsea Hotel, Toronto.
 
Read More

The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the Genitourinary Disease Site Committee Executives as well as Supportive Care Committee.

Read More

Published: February 05, 2020
Category: Publications
The most recent CCTG general review publications.
 
Read More

Published: February 05, 2020
Category: Publications
PR17 - Randomised Phase III Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET.
MEC4 - Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma.
IND205 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer (CRPC).
Read More

Published: February 05, 2020
Category: Publications
PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020

ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer.

Read More

Published: February 05, 2020
Category: Office of the Director

As 2020 begins, I wanted to take a moment to reflect on the hard work and accomplishments of our network of researchers and collaborators, both nationally and internationally, over the past year.

This year we supported 67 ongoing trials while working with our scientific network to activate 15 new trials of which 10 are being led by CCTG. This includes the IND234 trial that opened three new treatment arms this year—IND234 is the first trial to evaluate a precision medicine approach for patients with advanced prostate cancer using liquid biopsies for genomic testing.

Read More